AndroGel Pediatric (Under 12) Caregiver Administration Guidance

Why Children Under 12 Face a Real Risk from AndroGel

AndroGel is not prescribed to children under 12. The danger is indirect: testosterone transfers from the skin of an adult user to a child through ordinary physical contact such as hugging, being lifted, or sharing a bed. The FDA issued a Black Box Warning specifically for this scenario after receiving case reports of young children developing premature pubic hair, clitoral or penile enlargement, and advanced bone age following household exposure to testosterone gels. [1]

The FDA Black Box Warning in Plain Language

The FDA label for AndroGel states: "Virilization has been reported in children who were secondarily exposed to testosterone gel. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel." [1] That warning is not theoretical. The FDA MedWatch database documented multiple pediatric cases before the agency required manufacturers to update labeling in 2009. [2]

How Transfer Actually Happens

Testosterone transfers through direct skin-to-skin contact. Studies measuring residual testosterone on treated skin show that transfer drops significantly after washing but remains detectable for up to two hours if the site is uncovered and unwashed. [3] A child who climbs onto a caregiver's shoulders, rests a cheek against an untreated chest, or shares towels can receive a pharmacologically relevant dose. The Endocrine Society notes that even transient exposure repeated daily can produce measurable serum testosterone elevation in a prepubertal child. [4]

What "Virilization" Means for a Young Child

Virilization in a child under 12 includes:

• Premature pubic or axillary hair growth
• Enlargement of the clitoris (girls) or penis and testes (boys)
• Acne appearing outside normal infant milia
• Accelerated linear growth and advanced bone age on X-ray
• Increased aggressive or sexually precocious behavior

Bone age advancement is particularly concerning because it can close growth plates early, permanently reducing adult height. A 2010 case series published in Pediatrics documented advanced bone age in five children aged 9 months to 5 years after household testosterone gel exposure, with bone ages running 1 to 3 years ahead of chronological age at diagnosis. [5]

Safe Application: Step-by-Step Protocol for Caregivers

Every caregiver living with or regularly caring for an AndroGel user needs a standardized routine. Consistency is the only reliable protection.

Choosing the Right Application Site

The FDA-approved application sites for AndroGel 1.62% are the upper arms and shoulders. AndroGel 1% may also be applied to the abdomen. [1] Caregivers should favor shoulder and upper-arm sites over the abdomen when children are present, because clothing covers those sites more completely. Avoid the inner arms or areas that clothing does not reliably cover during childcare.

The Application Sequence

Follow this exact sequence every time:

1. Apply AndroGel to clean, dry skin on the upper arms or shoulders immediately after showering if possible.
2. Allow the gel to dry completely. Drying typically takes 3 to 5 minutes under normal room temperature. Do not speed-dry with a fan directed at a child's breathing zone.
3. Wash both hands thoroughly with soap and water for at least 20 seconds. The CDC hand-washing guidelines recommend covering all surfaces of both hands. [6]
4. Put on a clean shirt that fully covers the application site before any child contact.
5. Keep the shirt on until the next shower or for a minimum of 2 hours after application. [1]

What to Do Before Child Contact Is Unavoidable

If a caregiver must handle a child before the 2-hour window or before a shirt is available, wash the application site with soap and water first. This step reduces but does not eliminate transfer risk. The FDA label explicitly states that washing the application site with soap and water before skin contact reduces transfer. [1]

A practical decision framework for caregivers: think of AndroGel application as a three-gate system. Gate 1 is the application itself (correct site, correct dose). Gate 2 is washing hands immediately. Gate 3 is covering the site with clothing. All three gates must close before child contact. If any gate is missed, washing the site before contact is the fallback, not the routine.

Dose and Formulation Details Caregivers Should Know

Understanding the product helps caregivers respect the risk.

AndroGel 1% vs. 1.62%: Concentration Differences

AndroGel 1% delivers 50 mg testosterone per 5 g unit-dose packet or per 4 pump actuations. AndroGel 1.62% delivers 20.25 mg per pump actuation, with typical adult doses ranging from 40.5 mg (2 pumps) to 81 mg (4 pumps) daily. [1] Higher-concentration formulations deposit more testosterone per unit area of skin, which means transfer per contact is potentially greater if the site is not covered.

Absorption and Residual Skin Concentration

After application of AndroGel 1.62%, approximately 10% of the applied testosterone dose is absorbed systemically over 24 hours. [1] The remaining 90% stays largely on the skin surface or in the uppermost skin layers during the first two hours, making that window the highest-risk period for transfer. A pharmacokinetic study cited in the AndroGel prescribing information showed that residual skin concentrations fell by more than 80% after a single soap-and-water wash. [1]

Pump vs. Packet Dosing

Both pump and packet formulations carry the same exposure risk. Pumps reduce spillage compared with tearing open packets, but caregivers should prime the pump away from children and dispose of any tissue used to wipe the pump tip promptly and out of reach of children.

Recognizing Accidental Exposure in a Child Under 12

Early recognition allows prompt evaluation and removal of the exposure source before permanent changes occur.

Early Signs to Watch For

Parents and pediatricians should look for:

• Any pubic, axillary, or facial hair before age 8 in girls or age 9 in boys (standard Tanner Stage 1 definitions per the American Academy of Pediatrics) [7]
• Genital growth inconsistent with age
• Acne in a child under 7
• Rapid increase in height velocity documented at well-child visits
• Mood changes, increased irritability, or unusually aggressive behavior in a toddler or young child

When to Call the Pediatrician

Call the child's pediatrician the same day any of the signs above appear. Do not wait for the next scheduled well-child visit. Early intervention, primarily removing the testosterone source, can halt progression and allow partial regression of some changes. Bone age X-ray (typically a left wrist film) and a serum total testosterone level will be the first investigations ordered. [4]

Reporting to the FDA

Caregivers and clinicians can and should submit adverse event reports through MedWatch at fda.gov/safety/medwatch. Reporting secondary exposure cases strengthens the evidence base and may prompt additional label revisions.

Storage, Disposal, and Household Safety Practices

Testosterone gel does not pose risk only during application. Improper storage and disposal create additional hazard.

Safe Storage

• Store AndroGel at room temperature, 59°F to 86°F (15°C to 30°C). [1]
• Keep packets and pump containers in a locked cabinet or high shelf entirely out of a child's reach.
• Never leave open packets on countertops, bathroom shelves, or nightstands accessible to a child.
• Do not store in gym bags that children may access.

Disposing of Used Packets and Containers

• Fold used packets inward and place immediately in a trash can with a lid, preferably one that requires adult hand strength to open.
• FDA guidance on pharmaceutical disposal recommends household hazardous waste programs or drug take-back locations for unused testosterone products. [8]
• Do not flush testosterone gel packets unless a take-back option is unavailable and the FDA flush list specifically includes the product. As of the current label, AndroGel is not on the FDA flush list. [8]

Shared Bathroom Surfaces

Testosterone gel transferred to a bathroom counter or towel retains activity. Designate a separate towel for the AndroGel user and wash it separately. Wipe down any counter surfaces where gel may have dripped before children use the bathroom.

Special Scenarios Caregivers Often Ask About

Swimming and Water Exposure

The AndroGel 1.62% prescribing information states that patients should wait at least 2 hours after application before swimming or showering to ensure adequate absorption. [1] For child-safety purposes, if a caregiver applies gel and then supervises children in a pool or bath, the 2-hour coverage-and-washing rule still applies. Water contact does not substitute for the hand-washing and clothing steps.

Overnight Sleeping Arrangements

Children who co-sleep with an AndroGel user face repeated nightly exposure risk. The safest approach is for the caregiver to apply gel in the morning, shower before bedtime to remove any residual, and wear a shirt to bed. Some prescribers recommend switching to morning application schedules specifically to allow a full daytime wash cycle before nighttime child contact. [4]

School-Age vs. Toddler Risk

Toddlers and infants carry higher risk because they have more skin-to-skin contact with caregivers and cannot report symptoms. School-age children under 12 still face risk but typically have less direct physical contact. Regardless of the child's age, the protocols above apply equally. The FDA label does not specify a lower age limit of concern; any child under 12 is addressed by the warning. [1]

Grandparent and Non-Parental Caregiver Scenarios

Any adult using AndroGel who regularly cares for a child under 12, including grandparents, babysitters, or family members, must follow the same protocols. The prescribing physician should counsel not just the patient but any household member who provides childcare.

What the Prescribing Physician Should Document

Physicians prescribing AndroGel to patients who live with or regularly care for children under 12 have a specific counseling responsibility.

Required Counseling Points per FDA Label

The AndroGel prescribing information lists explicit counseling points for patients with children in the household. [1] These include:

• Apply only to areas covered by a short-sleeve T-shirt.
• Wash hands immediately after application.
• Cover the site with clothing after the gel dries.
• Avoid skin-to-skin contact with children until the application site has been washed.
• Inform all household members and caregivers of the risk.

Documenting Patient Understanding

A brief note confirming that the patient was counseled on pediatric secondary exposure risk, understood the application and coverage protocol, and was given the FDA Medication Guide (which must be dispensed with every AndroGel prescription per FDA requirements) provides both clinical and medico-legal documentation. [1]

The Endocrine Society Clinical Practice Guideline on male hypogonadism (2018) states: "Clinicians should counsel patients who use topical testosterone preparations about the potential for transfer to women and children and should advise patients to take precautions to prevent transfer." [4]

Alternative Testosterone Formulations When Children Are Present

For patients who cannot reliably follow the contact-prevention protocol, a different testosterone delivery route may be safer.

Intramuscular and Subcutaneous Injections

Testosterone cypionate and testosterone enanthate injections carry no secondary exposure risk from skin contact. Testosterone cypionate 200 mg/mL is widely used on a 1- to 2-week injection schedule, and weekly subcutaneous testosterone cypionate at lower volumes (typically 50 to 100 mg/week) has gained use in men seeking more stable serum levels. [9] There is no transfer concern with injectable formulations.

Testosterone Pellets

Subcutaneous pellet implants (Testopel, typically 150 to 450 mg implanted every 3 to 6 months) have no skin transfer risk and may be appropriate for patients where gel adherence to safety protocols is uncertain. [10]

Nasal Testosterone Gel

Natesto (testosterone 4.5% nasal gel) requires 3-times-daily dosing but confines testosterone to the nasal cavity, eliminating skin-surface transfer risk entirely. [11] This option may be appropriate for caregivers of young children who find the AndroGel safety protocol difficult to maintain consistently.

Prescribers should discuss these alternatives openly with patients who live with children under 12, rather than assuming the gel protocol will be followed perfectly in practice.